M&As this week: Venaxis, M Pharmaceutical, Horizon Pharma
Venaxis plans to expand its business through its recent acquisition of BiOptix Diagnostics, a medical device company.
Venaxis plans to expand its business through its recent acquisition of BiOptix Diagnostics, a medical device company.
Venaxis has acquired approximately 98% of BiOptix’s voting shares for 14% of the former’s post-deal outstanding common shares.
"The transaction will enable Horizon Pharma to expand its presence into European and other international markets."
M Pharmaceutical announced to expand its business into women’s health market by acquiring an undisclosed company with an FDA-approved product.
The acquirer is a clinical-stage company that develops technologies for obesity and weight management, whereas the target company is a private pharmaceutical company.
Horizon Pharma has entered a definitive agreement to acquire all outstanding and issued shares of Raptor Pharmaceutical for a purchase consideration of $800m, which is expected to be completed in November.
The transaction will enable Horizon Pharma to expand its presence into European and other international markets, strengthen its business revenue across orphan, rheumatology and primary care, and focus on rare diseases.